Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Mucositis 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 131Cetuximab 80Radiotherapy 76Docetaxel 59Carboplatin 46pembrolizumab 45Paclitaxel 44Fluorouracil 42Radiotherapy, Intensity-Modulated 35Drug Therapy 17Radiation 14Nivolumab 14Gefitinib 14Gemcitabine 13Surgical Procedures, Operative 12Oxaliplatin 11Erlotinib Hydrochloride 11130-nm albumin-bound paclitaxel 11Pemetrexed 10Celecoxib 10Capecitabine 10Bevacizumab 10tislelizumab 9Filgrastim 9Amifostine 9Albumin-Bound Paclitaxel 9durvalumab 7atezolizumab 7Chemoradiotherapy 7toripalimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Head and Neck Neoplasms × kang-lai-te × Clear all
NCT03101514 2021-06-23

Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study

First Affiliated Hospital of Harbin Medical University

Phase 2 Completed
53 enrolled 11 charts
Head & NeckOther

Head and Neck Neoplasms, Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡